Patents by Inventor Tongjie XU

Tongjie XU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY DRUG CONJUGATE
    Publication number: 20230405141
    Abstract: Provided is an antibody drug conjugate, specifically comprising a therapeutic antibody moiety, an intermediate linker moiety and a cytotoxic drug moiety which are linked. The therapeutic antibody moiety is an antibody against an HER2 target. The cytotoxic drug moiety is a camptothecin topoisomerase I inhibitor. The cytotoxic drug moiety or the linker-cytotoxic drug moiety is modified by means of deuterium substitution. The antibody drug conjugate can be used for the prevention or treatment of cancers.
    Type: Application
    Filed: August 13, 2021
    Publication date: December 21, 2023
    Inventors: Xiquan ZHANG, Tianxi CHEN, Weiwei FENG, Bing ZHANG, Xiaoqi TANG, Tongjie XU, Xiaojin WANG, Huace SHENG, Zhengping ZHANG, Hua WANG, Yong GAO
  • SINGLE VARIABLE DOMAIN AND ANTIGEN BINDING MOLECULE BINDING BCMA
    Publication number: 20230265181
    Abstract: An immunoglobulin single variable domain and antigen binding molecule binding BCMA, specifically comprising an immunoglobulin single variable domain and antigen binding molecule, a nucleic acid for encoding the binding molecule, a vector containing the nucleic acid, a cell containing the vector, and a pharmaceutical composition containing the above.
    Type: Application
    Filed: August 16, 2021
    Publication date: August 24, 2023
    Applicant: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Zipeng ZHEN, Meijuan XIE, Xiuzhen DU, Yimin MA, Bing ZHANG, Tongjie XU, Xiquan ZHANG
  • BCMA-BINDING SINGLE VARIABLE STRUCTURAL DOMAIN AND ANTIGEN-BINDING MOLECULE
    Publication number: 20230193292
    Abstract: A BCMA-binding immunoglobulin single variable structural domain and an antigen-binding molecule including an immunoglobulin single variable structural domain and an antigen-binding molecule, a nucleic acid encoding the above, a vector containing the nucleic acid, a cell containing the vector, and a pharmaceutical composition containing the above, as well as a therapeutic use thereof.
    Type: Application
    Filed: August 16, 2021
    Publication date: June 22, 2023
    Applicant: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Zipeng ZHEN, Meijuan XIE, Xiuzhen DU, Yimin MA, Bing ZHANG, Tongjie XU, Xiquan ZHANG
  • FUSION PROTEIN TARGETING PD-L1 AND TGF-ß AND USE THEREOF
    Publication number: 20220289825
    Abstract: Provided are a fusion protein targeting PD-L1 and TGF-? and use thereof. The fusion protein is a fusion protein comprising an antibody or antigen-binding fragment that specifically binds to human PD-L1 and a human TGF?RII binding domain. Further provided are a polynucleotide encoding the fusion protein, a host cell containing the polynucleotide, and the use of the fusion protein in the preparation of an anti-tumor drug.
    Type: Application
    Filed: August 28, 2020
    Publication date: September 15, 2022
    Inventors: Wei ZHAO, Yingchun LI, Lianxiang XIE, Yamin LU, Haili LV, Xiuzhen DU, Tongjie XU, Yanju CHENG, Xiquan ZHANG